Research programme: humanised antibody therapeutics - CSL

Drug Profile

Research programme: humanised antibody therapeutics - CSL

Latest Information Update: 14 Apr 2010

Price : $50

At a glance

  • Originator CSL
  • Developer Arana Therapeutics; CSL
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 14 Apr 2010 Preclinical development is ongoing in Australia
  • 24 Aug 2009 This programme is in active development
  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top